LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

27.7 -0.4

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.08

Max

27.91

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-28M 22M
Pardavimai	4.3M 244M
P/E Sektoriaus vid.	10.28 57.833
Pelnas, tenkantis vienai akcijai	1.08
Pelno marža	9.224
Darbuotojai	293
EBITDA	-22M 52M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+48.11% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	64M 1.6B
Ankstesnė atidarymo kaina	28.1
Ankstesnė uždarymo kaina	27.7

Naujienos nuotaikos

By Acuity

75%

25%

323 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-18 22:51; UTC

Uždarbis

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

2026-03-18 21:40; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

2026-03-18 20:31; UTC

Uždarbis

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

2026-03-18 23:49; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

2026-03-18 23:31; UTC

Rinkos pokalbiai

Gold Rises on Likely Technical Recovery -- Market Talk

2026-03-18 22:49; UTC

Rinkos pokalbiai

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

2026-03-18 22:41; UTC

Rinkos pokalbiai

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

2026-03-18 22:36; UTC

Uždarbis

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

2026-03-18 22:24; UTC

Uždarbis

AIA Group Announces New Share Buyback of $1.7B >1299.HK

2026-03-18 22:23; UTC

Uždarbis

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

2026-03-18 22:23; UTC

Uždarbis

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

2026-03-18 21:58; UTC

Uždarbis

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

2026-03-18 21:55; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-03-18 21:55; UTC

Rinkos pokalbiai

Uždarbis

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

2026-03-18 21:40; UTC

Rinkos pokalbiai

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

2026-03-18 21:16; UTC

Rinkos pokalbiai

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

2026-03-18 21:00; UTC

Svarbiausios naujienos

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

2026-03-18 20:58; UTC

Uždarbis

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

2026-03-18 20:41; UTC

Uždarbis

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026-03-18 20:29; UTC

Uždarbis

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026-03-18 20:25; UTC

Uždarbis

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026-03-18 20:17; UTC

Uždarbis

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

2026-03-18 20:14; UTC

Rinkos pokalbiai

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

2026-03-18 20:09; UTC

Uždarbis

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

2026-03-18 20:07; UTC

Uždarbis

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

2026-03-18 20:06; UTC

Uždarbis

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

2026-03-18 20:04; UTC

Uždarbis

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

2026-03-18 20:04; UTC

Uždarbis

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

2026-03-18 20:04; UTC

Uždarbis

Micron Technology Sees 3Q Gross Margin About 81% >MU

2026-03-18 20:03; UTC

Uždarbis

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

48.11% į viršų

12 mėnesių prognozė

Vidutinis 41.25 USD 48.11%

Aukščiausias 62 USD

Žemiausias 25 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

323 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.